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Abstract
Introduction: Adipose stem cells (ASCs) secrete many trophic factors that can stimulate tissue repair, including
angiogenic factors, but little is known about how ASCs and their secreted factors influence cartilage regeneration.
Therefore, the aim of this study was to determine the effects ASC-secreted factors have in repairing chondral
defects.
Methods: ASCs isolated from male Sprague Dawley rats were cultured in monolayer or alginate microbeads
supplemented with growth (GM) or chondrogenic medium (CM). Subsequent co-culture, conditioned media, and
in vivo cartilage defect studies were performed.
Results: ASC monolayers and microbeads cultured in CM had decreased FGF-2 gene expression and VEGF-A
secretion compared to ASCs cultured in GM. Chondrocytes co-cultured with GM-cultured ASCs for 7 days had
decreased mRNAs for col2, comp, and runx2. Chondrocytes treated for 12 or 24 hours with conditioned medium
from GM-cultured ASCs had reduced sox9, acan, and col2 mRNAs; reduced proliferation and proteoglycan synthesis;
and increased apoptosis. ASC-conditioned medium also increased endothelial cell tube lengthening whereas
conditioned medium from CM-cultured ASCs had no effect. Treating ASCs with CM reduced or abolished these
deleterious effects while adding a neutralizing antibody for VEGF-A eliminated ASC-conditioned medium induced
chondrocyte apoptosis and restored proteoglycan synthesis. FGF-2 also mitigated the deleterious effects VEGF-A
had on chondrocyte apoptosis and phenotype. When GM-grown ASC pellets were implanted in 1 mm non-critical
hyaline cartilage defects in vivo, cartilage regeneration was inhibited as evaluated by radiographic and equilibrium
partitioning of an ionic contrast agent via microCT imaging. Histology revealed that defects with GM-cultured ASCs
had no tissue ingrowth from the edges of the defect whereas empty defects and defects with CM-grown ASCs
had similar amounts of neocartilage formation.
Conclusions: ASCs must be treated to reduce the secretion of VEGF-A and other factors that inhibit cartilage
regeneration, which can significantly influence how ASCs are used for repairing hyaline cartilage.
Introduction
Adult stem cells, such as adipose stem cells (ASCs) are
an emerging clinical option for treating tissue damage
and diseases because of their accessibility and ability to
differentiate into multiple cell lineages [1,2]. More
recently, ASCs and other adult stem cells have been
shown to secrete a wide range of trophic factors that
can stimulate regeneration of tissues from multiple
lineages [3]. As these cell therapies become more preva-
lent in different clinical procedures, their secretory pro-
files need to be more thoroughly investigated in terms
of the role stem cell-secreted factors have in tissue
regeneration and in possible side effects.
Hyaline cartilage is the most prevalent cartilaginous tis-
sue found in the body, with adult stem cell therapies used
to regenerate hyaline cartilage in the knee and trachea of
humans [4,5] and to repair cartilage in the larynx, bron-
chial stump, and growth plate of animals in preclinical stu-
dies [6-8]. Unlike most other tissues, hyaline cartilage is an
avascular and aneural tissue that has complex spatial varia-
tion in its mechanical properties and composition despite
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a relatively homogeneous cell population. Therefore, adult
stem cell therapies used for repair of chondral defects
must secrete factors that stimulate synthesis of specific
proteoglycans and collagens without facilitating the infil-
tration of other tissues, especially blood vessel formation,
or enabling hypertrophic differentiation of chondrocytes
typical of endochondral ossification.
Although the secretory profile of ASCs for cartilage
regeneration has been investigated [9], an in-depth study
determining the role ASC-secreted factors have in chon-
drocyte proliferation, phenotype, and cartilage regenera-
tion has yet to be conducted. Additionally, techniques
such as microencapsulation and differentiation medium
treatments have been used to improve the regenerative
capacity for mesenchymal stem cells [10-12], but no
study has investigated the effects these two parameters
have on the secretion of trophic factors from ASCs.
Therefore, the overall objective of this study was to deter-
mine the role ASC-secreted trophic factors have in carti-
lage regeneration. The effect of microencapsulation and
chondrogenic medium treatment on angiogenic factor
production was first determined. Then co-culture and
conditioned media studies were conducted to determine
how ASC-paracrine signaling and ASC-secreted factors
affect chondrocytes. Finally, ASCs were implanted into a
chondral defect in the xiphoid to determine the effect
ASCs have on hyaline cartilage regeneration.
Materials and methods
Cell isolation
For each experiment, ASCs were isolated from inguinal
fat pads of six 125-g male Sprague Dawley rats (Harlan
Laboratories, Indianapolis, IN, USA) under a protocol
approved by the Institutional Animal Care and Use
Committee of the Georgia Institute of Technology as
described in detail previously [13]. ASCs from the six
animals were then combined and cultured in Lonza
mesenchymal stem cell growth medium (GM) (Lonza,
Walkersville, MD, USA). After one passage, these cells
were positive for CD73 and CD271 and negative for
CD45 [13]. Non-matching costochondral chondrocytes
from the ribs of a different set of six 125-g male Spra-
gue Dawley rats were isolated and combined as
described previously [14]. Primary chondrocytes were
cultured in DMEM containing 10% fetal bovine serum
(FBS) and 50 μg/mL ascorbic acid (Invitrogen) until the
fourth passage prior to experimental analysis. These
cells continue to express type II collagen, aggrecan, and
cartilage oligomeric matrix protein [14].
Microencapsulation
Once primary ASCs reached 90% confluence, cells were
trypsinized and microencapsulated in 20 mg/mL low
molecular weight (approximately 150 kDa) alginate
(FMC BioPolymer, Sandvika, Norway) with a high man-
nuronate to guluronate ratio (40% guluronate) at a
concentration of 25 × 106 cells/mL using a Nisco Encap-
sulator VAR V1 LIN-0043 (Nisco Engineering AG,
Zurich, Switzerland) as previously described [15]. The
microbeads were washed three times in GM prior to cell
culture studies. First passage ASCs were also plated in
6-well plates (Figure 1A).
ASC cell culture
Once first passage ASCs reached 90% confluence (Figure
1A), ASC monolayers and microbeads were then treated
for 5 days with either GM or chondrogenic medium
(CM) consisting of high-glucose DMEM with 1 mM
sodium pyruvate (Mediatech, Manassas, VA, USA),
40 μg/mL proline (Sigma, St. Louis, MO, USA), 50 μg/
mL ascorbate-2-phosphate (Sigma), 1% ITS+ (Sigma),
100 nM dexamethasone (Sigma), 10 ng/mL recombinant
human transforming growth factor beta-1 (TGF-b1)
(R&D Systems, Minneapolis, MN, USA) and 100 ng/mL
recombinant human bone morphogenic protein 6 (BMP-
6) (PeproTech, Rocky Hill, NJ, USA). Once media were
changed on the fifth day, RNA was collected after 8 hours
as described below while media and ASCs lysed in 0.05%
Triton X-100 were collected after 24 hours. Fourth pas-
sage chondrocytes cultured in DMEM, 10% FBS, and
50 μg/mL ascorbic acid and Sprague Dawley-derived clone
9 liver cells (ATCC, Manassas, VA, USA) cultured in
F12K medium and 10% FBS served as controls. All media
contained 1% penicillin and streptomycin.
Growth factor expression and production
Microbeads were un-cross-linked in 82.5 mM sodium
citrate (Sigma), pelleted at 500 g for 10 minutes and
washed two more times in sodium citrate to remove any
residual alginate. TRIzol reagent (Invitrogen, Grand
Island, NY, USA) was added to the resulting cell pellet,
homogenized using a QIAshredder (QIAGEN, Valencia,
CA, USA), and RNA was isolated using chloroform and
an RNeasy Kit (Qiagen) as previously described [16].
Then 1 μg RNA was reverse-transcribed to cDNA using
a High Capacity Reverse Transcription cDNA kit
(Applied Biosystems, Carlsbad, CA, USA). Gene expres-
sions were quantified as previously described [17].
Primers were designed using Beacon Designer software
(Premier Biosoft, Palo Alto, CA, USA) and synthesized by
Eurofins MWG Operon (Huntsville, AL, USA) unless
otherwise noted (Table 1). Vascular endothelial growth
factor (VEGF)-A and fibroblast growth factor (FGF)-2
production over the last 24 hours of culture was quanti-
fied using ELISA (R&D Systems) and normalized to
DNA content measured with a Quant-iT PicoGreen kit
(Invitrogen). Quantified mRNA levels are referred to by
the name of the gene (for example, fgf2, vegfa, runx2)
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whereas quantified protein levels are referred to by the
name of the growth factor (for example FGF-2, VEGF-A).
Paracrine signaling
ASC-chondrocyte co-culture
To assess the effects that paracrine signaling between
ASCs and chondrocytes have on chondrocyte pheno-
type, the two cell types were co-cultured in a trans-well
system (Figure 2A). Initial studies determined the num-
ber of microbeads per insert needed to have the same
cell number as ASC-confluent trans-well inserts. ASC
monolayers and microbeads were treated with GM or
with CM for 5 days in 0.2 μm high density cell culture
inserts (BD Biosciences, Franklin Lakes, NJ, USA). ASC
cultures and inserts were then washed in DMEM three
times and added to wells with confluent chondrocytes.
The two cell groups were then cultured in 4.5 mL
DMEM + 10% FBS. After 7 days, RNA was isolated
from the chondrocytes to quantify chondrogenic gene
expression. Microencapsulated clone 9 liver cells served
as a control.
Chondrocyte cultures treated with ASC-conditioned media
To assess the effects ASC-secreted factors have on them,
chondrocytes were cultured in different ASC-conditioned
media (Figure 2C) obtained from T-75 flasks. Initial stu-
dies determined the number of microbeads per T-75
needed to have the same cell number as ASC-confluent
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Figure 1 Effects of microencapsulation and chondrogenic medium (CM) on angiogenic factor expression and secretion. (A) Diagram of
adipose stem cell (ASC) monolayer (ML) and microbead (μB) treatments with growth medium (GM) and CM prior to mRNA and media
collections. (B) mRNA levels isolated after 5 days of culture and (C) growth factor production over the last 24 hours from ASCs, chondrocytes
(chond), and liver cells (liv) (n = 6 ± SE). *P < 0.05 vs. chond; #P < 0.05 vs. ASCs; ^P < 0.05 vs. ASC microbeads (ASC + μB).
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monolayers and microbeads were treated with GM or
CM for 5 days in T-75s. After the fifth day of treatment,
ASC monolayers and microbeads were washed in DMEM
three times and 10 mL DMEM + 10% FBS were added to
each culture. After 24 hours, media containing the ASC-
secreted factors were collected then immediately added
to confluent chondrocyte cultures. After 12 hours in
ASC-conditioned medium, RNA was isolated from chon-
drocytes to quantify chondrogenic gene expression. To
assess chondrocyte phenotype, apoptosis, and prolifera-
tion, the following assays were performed after 24 hours
of treatments with ASC-conditioned medium. These
time points were selected based upon previous studies
investigating the effects of different signaling molecules
on chondrocytes [18-20]. Conditioned medium from
microencapsulated clone 9 liver cells served as a control.
Chondrocyte responses
Incorporation of [3H]-thymidine
DNA synthesis was assayed by measuring [3H]-thymi-
dine incorporation as described previously [19]. Forty
%-confluent chondrocytes were treated with DMEM +
1% FBS to induce quiescence. Four hours before harvest,
[3H]-thymidine was added to a final concentration of
0.25 μCi/mL. Radioactivity in trichloroacetic acid-insolu-
ble cell precipitates was measured by liquid scintillation
spectroscopy.
Incorporation of [35S]-sulfate
Proteoglycan synthesis was assayed by measuring [35S]-
sulfate incorporation as previously described [21]. The
[35S]-sulfate was added to a final concentration of 18
μCi/mL for the final 4 hours of culture. Only [35S]-sulfate
incorporation in the monolayer was measured since less
than 15% of total radiolabeled proteoglycan production is
secreted into the medium [20]. The [35S]-sulfate incor-
poration was normalized to protein content measured
with a Pierce Macro BCA protein kit (ThermoScientific,
Rockford, IL, USA).
Alkaline phosphatase activity
Alkaline phosphatase-specific activity in chondrocyte
lysates was measured as a function of release of p-nitrophe-
nol from p-nitrophenylphosphate as previously described
[22] and normalized to protein content measured with a
Pierce Macro BCA protein kit (ThermoScientific).
Effects of ASCs on chondrocyte apoptosis
DNA fragmentation
To assess the effects of ASC-secreted factors on DNA
fragmentation, confluent chondrocytes were pulsed with
[3H]-thymidine for 4 hours prior to treatment with ASC-
conditioned medium. Chondrocytes were lysed and cen-
trifuged at 13,000 g for 15 minutes to separate intact
DNA from fragmented DNA as previously described
[18]. The amount of incorporated [3H]-thymidine was
determined in each fraction to establish the total amount
of fragmented DNA.
Caspase-3 activity
Caspase-3 activity was determined using a colorimetric
CaspACE™ Assay System from Promega (Madison, WI,
USA) following the manufacturer’s protocol, 24 hours
after ASC-conditioned media were added to confluent
chondrocytes. Caspase-3 activity was normalized to total
protein content measured with a Pierce 660 nm protein
assay (ThermoScientific).
Effect of secreted factors on angiogenic response
Fibrin gel assay
Angiogenic responses to different ASC-conditioned
media were assessed with endothelial cells cultured in a
fibrin gel assay as previously described [23]. Human aor-
tic endothelial cells (HAECs) (Lonza) were plated in
endothelial cell basal medium (EGM)-2 (Lonza) at 5 ×
103 cells/well on fibrin gel and cultured at 37°C for
24 hours. At 24 hours, medium was removed, a second
layer of fibrin was added on top, and ASC-conditioned
media were added. After 12 hours, images were taken for
morphometric analysis and total endothelial tube length
was determined using Image Pro Plus.
Role of VEGF-A and FGF-2
To determine the effect exogenous VEGF-A and FGF-2
have on chondrocytes, 1 ng/mL and 20 ng/mL of recom-
binant human VEGF-A165, and recombinant human
FGF-2 (R&D Systems), were added to monolayer cultures
of fourth-passage chondrocytes. These concentrations
were selected based upon a prior dose-response study on
mesenchymal stem cells [24], and because measured
Table 1 Primer sequences
Gene Direction Sequence Accession
Number
Acan Sense GCT TCG CTG TCC TCA ATG C NM_022190.1
Antisense AGG TGT CAC TTC CCA ACT
ATC C
Col2 Sense CGAGTATGGAAGCGAAGG NM_012929.1
Antisense GCTTCTTCTCCTTGCTCTTGC
Comp Sense AGT GAC AGC GAT GGT GAT
GG
NM_012834.1
Antisense TCC CCG TCC TGG TCT TGG
Fgf2 Sense Global Gene Sequence (Qiagen) NM_019305.2
Antisense
Pdgfa Sense GAGGAGACGGATGTGAGG NM_012801.1
Antisense ACGGAGGAGAACAAAGACC
Runx2 Sense TTGGACACCTTGGACGCTAATT NM_053470.2
Antisense AGA GGC AGA AGT CAG AGG
Sox9 Sense GTG GGA GCG ACA ACT TTA CC XM_003750950.1
Antisense ATC GGA GCG GAG GAG GAG
Vegfa Sense GGACATCTTCCAGGAGTACC NM_031836.2
Antisense CGTCTTGCTGAGGTAACC
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VEGF-A concentrations among the different conditioned
media groups ranged from 1 to 20 ng/mL. To determine
the effect VEGF-A and FGF-2 secreted by ASCs have on
chondrocytes, conditioned medium from GM-treated
ASC monolayers was supplemented with 1 μg/mL goat
anti rat IgG, 1 μg/mL goat anti-rat VEGF-A neutralizing
antibody, or 1 μg/mL goat anti-rat FGF-2 neutralizing
antibody (R&D Systems) and added to fourth-passage
chondrocyte monolayers as determined by the manufac-
turer’s protocol. After 24 hours, [35S]-sulfate incorporation,
caspase-3 activity, and incorporation of [3H]-thymidine
were measured as described above. DMEM + 10% FBS and
conditioned medium from ASC monolayers treated with
CM served as controls.
Xiphoid defect in vivo
To assess if ASCs would inhibit cartilage regeneration,
non-critically sized chondral defects were made in the
xiphoids of 125-g male Sprague-Dawley rats as previously
described [25]. The protocol was approved by the Institu-
tional Animal Care and Use Committee of the Georgia
Institute of Technology and each group was tested in
seven rats. A full-thickness 1 mm cylindrical defect was
made in the center of the xiphoid using a dermal biopsy
punch (Mitex, Plainsboro, NJ, USA). This defect size was
chosen because cartilage regeneration was previously
observed after 35 days and the defect is large enough to
contain cell pellets 1 × 106 ASCs in size [25]. ASC mono-
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Figure 2 Effects of adipose stem cell (ASC) co-culture and ASC-conditioned media on chondrocyte mRNA levels. (A) Diagram of ASC co-
culture and (B) mRNA levels of chondrocytes after 7 days. (C) Diagram of ASC-conditioned media treatment and (D) mRNA levels of
chondrocytes after 12 hours. X-axis labels refer to treatments and culture type for ASCs and liver cells (Liv) prior to co-culture and conditioning,
which include growth medium (GM), chondrogenic medium (CM), monolayer (ML), and microbead (μB) (n = 6 ± SE). *P < 0.05 vs. control;
#P < 0.05 vs. ASCs, ^P < 0.05 vs. ASC microbeads (ASCs + μB).
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ASCs/pellet and implanted into the defect. Empty defects
and autografts (excised cartilage is re-implanted) served
as controls. To maintain groups in the defect and to
serve as an adhesion barrier, SepraFilm® (Genzyme,
Cambridge, MA, USA) was then placed on the dorsal and
ventral sides of the defect. Xiphoids were excised 35 days
post-surgery and examined as described below.
Radiographic imaging (Faxitron Bioptics, Lincolnshire,
IL, USA) was performed in the coronal plane at a vol-
tage of 22 mV and exposure time of 16 s to visualize
soft tissue penetration as previously described [25]. Four
observers with experience in examining radiographic
images then scored the images blinded, for the presence
of soft tissue penetration, with a score of 0 representing
no healing, a score of 0.5 representing partial healing,
and a score of 1 representing full healing. The average
score each observer gave for each group was used for
statistical analysis (n = 4).
Equilibrium partitioning of an ionic contrast agent via
micro-computed tomography (EPIC-μCT, μCT40,
SCANCO Medical, Brüttisellen, Switzerland) was used to
visualize the distribution of proteoglycans within the
xiphoid defects as previously described [25,26]. Xiphoids
were incubated in 40% Hexabrix (Mallinckrodt, St. Louis,
MO, USA) in PBS containing 1% proteinase inhibitor
cocktail (CalBiochem, Darmstadt, Germany) overnight
and scanned using pre-determined settings [25]. Low
x-ray attenuation (green/yellow) of three-dimensional
color images corresponded to regions of high proteogly-
can concentration; no, or high x-ray attenuation (black
and red/orange) indicated regions of low proteoglycan
concentration. To determine cartilage volume, user-
guided contours corresponding to a 1.1-mm cylinder
around the defect were drawn and evaluated at a 100 to
250 threshold range. This contour size was chosen so all
cartilage integrity, in-growth, and integration at the
defect edge would be taken into account. Thus, all groups
had positive cartilage volume since the evaluation volume
was larger than the defect volume.
After scanning, samples were washed in PBS for four
hours, fixed in 10% phosphate-buffered formalin for 48
hours, and embedded in paraffin. Serial sections, 7-μm
thick, were stained with H&E to highlight cells and
extracellular matrix on microscope images (DMLB;
Leica, Nussloch, Germany).
Statistical analysis
All in vitro experiments included six independent cul-
tures per treatment group to ensure sufficient power to
detect statistically significant differences. All in vitro
experiments were conducted multiple times to validate
the observations, but only data from a single representa-
tive experiment are shown and are expressed as means ±
standard error (SE). A power analysis determined that
seven samples per group were needed for the in vivo
study based on results from a previous study [25]. Statis-
tical analysis was conducted using analysis of variance
(ANOVA) with the post hoc Tukey test (GraphPad
Prism, La Jolla, CA, USA). Differences in means were
considered to be statistically significant if the P-value was
less than 0.05.
Results
Angiogenic growth factor production from ASCs
ASC monolayers and microbeads cultured in GM had
1.5 to 3.0 times higher levels of fgf2 and vegfa compared
to chondrocytes while CM reduced both vegfa and fgf2
to levels similar to that of chondrocytes (Figure 1B). CM
did not influence pdgfa in ASCs, which was half the
mRNA level seen in chondrocytes. ASC monolayers and
microbeads secreted 10 to 30 times more VEGF-A than
chondrocytes, while CM reduced secretion by 3.0- to
3.5-fold (Figure 1C). FGF-2 secretion from ASC cultures
and chondrocytes was very low compared to VEGF-A
production.
Effect of ASC paracrine signaling and secreted factors on
chondrocyte gene expression
Chondrocytes co-cultured with ASC monolayers cul-
tured in GM experienced 3.5- to 4.0-fold reductions in
col2, comp, and runx2 compared to chondrocytes with
no co-culture (Figure 2B). However, CM-treated ASC
monolayers increased acan in chondrocytes and had no
effect on col2, comp, and runx2 in chondrocytes com-
pared to the control. GM-cultured ASC microbeads
reduced col2 in chondrocytes but CM-treated ASC
microbeads reduced col2, comp, and runx2 in chondro-
cytes compared to control. ASC co-cultures did not
affect sox-9 and co-culture with clone 9 liver cell
microbeads did not influence chondrocyte gene expres-
sion compared to the control.
Conditioned medium from GM-cultured ASC mono-
layers added to chondrocytes increased sox9 by 50%, acan
by 78%, and col2 by 35% compared to control medium
added to chondrocytes (Figure 2D). However, conditioned
medium from CM-treated ASC monolayers had no effect
on chondrogenic mRNA levels compared to control med-
ium. Conditioned medium from GM-cultured ASC
microbeads decreased acan, but conditioned medium
from CM-treated ASC microbeads had no effect on chon-
drocyte mRNA levels. Clone 9 liver cell microbeads
decreased acan in chondrocytes but had no effect on sox9,
col2, comp, or runx2.
Effect of ASC-secreted factors on proliferation,
phenotype, and apoptosis
Conditioned media from GM-cultured ASC monolayer
and microbeads decreased [35S]-sulfate incorporation by
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75% and 60% respectively (Figure 3B), had no effect on
alkaline phosphatase activity (Figure 3C), and decreased
[3H]-thymidine incorporation by approximately 76%
(Figure 3D) compared to chondrocytes treated with con-
trol medium. Treating ASC monolayers and microbeads
with CM prior to conditioned media collection elimi-
nated the deleterious effects ASC-secreted factors
had on chondrocytes (Figure 3B, D). Liver microbead-
conditioned medium did not affect [3H]-thymidine
incorporation, [35S]-sulfate incorporation, or alkaline
phosphatase activity (Figure 3B-D).
Conditioned medium from GM-cultured ASC mono-
layers increased caspase-3 activity 120%, bax/bcl expres-
sion 79%, and DNA fragmentation 114% compared to
control medium (Figure 3E-G). Treating ASC mono-
layers with CM prior to collecting conditioned medium
eliminated the apoptotic effects ASC-secreted factors had
on chondrocytes. Conditioned medium from ASC
microbeads cultured in GM did not increase apoptosis
compared to control medium. Conditioned medium
from liver microbeads had no effect on caspase-3 activity
and bax/bcl, but did increase DNA fragmentation com-
pared to the control (Figure 3E-G).
ASC monolayer and microbead-conditioned media
increased endothelial tube length by 2.6- and 2.0-fold
respectively (Figure 3G). Treating ASC monolayers and
microbeads with CM prior to conditioned media collec-
tion eliminated this angiogenic response. Conditioned
medium from liver microbeads had no effect on endothe-
lial tube length.
Effect of exogenous VEGF-A and FGF-2 on chondrocytes
The incorporation of 35S-sulfate was reduced by
approximately 30% and 50% with the addition of 1 ng/
mL and 20 ng/mL of VEGF-A, respectively (Figure 4A).
Adding FGF-2 at both 1 and 20 ng/mL alone had no
effect on 35S-sulfate incorporation but did eliminate the
inhibitory effect rhVEGF-A had on 35S-sulfate incor-
poration at both concentrations. Addition of VEGF-A at
concentrations of 1 ng/mL and 20 ng/mL significantly
increased caspase-3 activity by 32% and 84%, respec-
tively (Figure 4B). Adding 1 ng/mL of FGF-2 had no
effect on caspase-3 activity and did not reduce the apop-
totic effect of VEGF-A compared to the control. How-
ever, 20 ng/mL FGF-2 eliminated the apoptotic effect of
VEGF-A. VEGF-A and FGF-2 had a more limited effect
on chondrocyte proliferation, as only the 20 ng/mL
FGF-2 dosage increased [3H]-thymidine incorporation
(Figure 4C).
Effect of ASC-secreted VEGF-A and FGF-2 on
chondrocytes
ASC-conditioned medium with a goat-anti-rat IgG and
FGF-2 neutralizing antibody decreased [35S]-sulfate
incorporation by approximately 50% (Figure 5B), and
increased caspase-3 activity by approximately 94%
(Figure 5C) compared to control medium. Adding
VEGF-A neutralizing antibody to ASC-conditioned med-
ium eliminated both its deleterious effect on chondrocyte
phenotype and its apoptotic effect. ASC-conditioned
medium with or without VEGF-A or FGF-2 neutralizing
antibodies all decreased [3H]-thymidine incorporation
compared to control medium (Figure 5D). As previously
observed, conditioned medium from ASC monolayers
treated with CM had no effect on chondrocyte caspase-3
activity, [35S]-sulfate, and [3H]-thymidine incorporation
compared to control medium (data not shown).
Effect of ASCs in cartilage defects
Scoring of radiographic images showed that all seven
defects with autografts had partial or full healing and
three of seven empty defects had partial or full healing;
however, no more than two of seven defects with ASC
pellets had partial healin, whereas four of seven defects
with pellets of ASCs treated with CM had partial or full
healing (Figure 6A). Scores for healing for the empty
defects, defects with ASCs treated with CM, and defects
with autografts were all higher than for defects with ASC
pellets. Scores for defects with ASCs treated with CM
were not statistically different from scores for the empty
defects, and were lower than scores for defects with the
autografts (Figure 6A).
Proteoglycan was visible in EPIC-μCT images of empty
defects and defects with pellets of CM-treated ASCs but
absent from defects with pellets of GM-cultured ASCs
(Figure 6B). EPIC-μCT-calculated cartilage volume for
defects with ASC pellets was significantly smaller than
cartilage volume in both autografts and empty defects.
Defects with CM-treated ASCs had more cartilage than
defects with GM-cultured ASCs, but were not different
from empty defects (Figure 6B).
In histological sections of defects with autografts, early-
stage cartilage and infiltrating cells were starting to inte-
grate the graft with the surrounding xiphoid (Figure 6C).
Similar tissue deposition and cell infiltration was
observed for empty defects and defects with ASCs treated
with chondrogenic media. However, defects with ASCs
were infiltrated with surrounding epithelial tissue instead
and lacked the connective tissue that was observed in
empty defects (Figure 6C).
Discussion
This study is the first to definitively show that ASCs
secrete angiogenic factors that are detrimental for chon-
drocytes and can prevent cartilage regeneration. Specifi-
cally, ASCs secrete a relatively large amount of VEGF-A,
which can inhibit chondrocyte phenotype and lead to
chondrocyte apoptosis. Additionally, ASCs secrete factors
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Figure 3 Effects of adipose stem cell (ASC)-conditioned medium on chondrocyte phenotype, proliferation, apoptosis, and angiogensis.
(A) Diagram of ASC-conditioned media experiments, (B) [35S]-sulfate incorporation, (C) alkaline phosphatase activity, (D) [3H]-thymidine
incorporation, (E) caspase-3 activity, (F) bax/bcl2 mRNA levels, (G) DNA fragmentation, and (H) endothelial tube length. All experiments were
assayed after 24 hours of conditioned media treatment except for bax/bcl2 mRNA levels and endothelial tube length, which were measured
after 12 hours of treatment. X-axis labels refer to treatments and culture type for chondrocytes (Chond), ASCs, and liver cells (Liv) prior to
conditioning, which include growth medium (GM), chondrogenic medium (CM), monolayer (ML), and microbead (μB) (n = 6 ± SE). *P < 0.05 vs.
control; #P < 0.05 vs. ASCs; ^P < 0.05 vs. ASC microbeads (ASCs + μB).
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that negatively influence chondrocyte proliferation. Finally,
ASCs prevent cartilage regeneration in a non-critical, hya-
line cartilage defect in vivo. Despite these deleterious
effects, treating ASCs with chondrogenic medium can
reduce the expression and production of VEGF-A, elimi-
nate the damaging effects ASC-secreted factors have on
chondrocytes, and prevent the adverse effects ASCs have
on regenerating cartilage in vivo.
In addition to chondrogenic medium, microencapsula-
tion had a significant effect on VEGF-A and FGF-2
secretions. Specifically, microencapsulation had the
opposite effect of chondrogenic medium and increased
the secretion of these angiogenic factors. Hypoxia due
to the high cell density within the microbead may have
increased VEGF-A and FGF-2 secretions. Hypoxic con-
ditions can increase VEGF-A and FGF-2 secretion from
ASCs [27] since the genes for these angiogenic factors
have hypoxia response elements [28,29]. Although
we did not assay for hypoxic conditions within the
microbead, increasing cell concentrations within hydro-
gels has been shown to increase oxygen tension and gra-
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Figure 4 Effects of exogenous vascular endothelial growth factor (VEGF)-A and fibroblast growth factor (FGF)-2 on chondrocytes. (A)
[35S]-sulfate incorporation of chondrocytes treated with recombinant human VEGF-A and FGF-2, (B) caspase-3 activity of chondrocytes treated
with recombinant human VEGF-A and FGF-2, and (C) [3H]-thymidine incorporation of chondrocytes treated with recombinant human VEGF-A
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Figure 5 Effects of adipose stem cell (ASC)-secreted vascular epithelial growth factor (VEGF)-A and fibroblast growth factor (FGF)-2 on
chondrocytes. (A) Schematic outlining chondrocytes treated with ASC-conditioned medium with VEGF-A and FGF-2 neutralizing antibodies and
assayed for (B) [35S]-sulfate incorporation, (C) caspase-3 activity, and (D) [3H]-thymidine incorporation after 24 hours of treatment (n = 6 ± SE). *P
< 0.05 vs. control; #P < 0.05 vs. ASCs.
Lee et al. Stem Cell Research & Therapy 2012, 3:35
http://stemcellres.com/content/3/4/35
Page 9 of 13
variable in controlling growth factor secretion from ASC
microbeads.
Previous studies have extensively studied the secretory
profiles of bone marrow-derived mesenchymal stem cells
(MSCs) and ASCs, showing that they not only secrete sev-
eral factors that can facilitate cartilage regeneration [9,31],
but that they also secrete a large amount of angiogenic
factors [32,33]. VEGF-A, an important initiator and med-
iator of angiogenesis [34,35], was secreted in large quanti-
ties by ASC monolayers and microbeads, decreased
chondrocyte proteoglycan production, and induced chon-
drocyte apoptosis in the current study. Although VEGF-A
typically elicits anabolic responses from most cell types,
this growth factor has catabolic effects on chondrocytes
and has been shown to induce matrix metalloproteinase
expression in these cells [36]. Although VEGF-A was not
responsible for reduced chondrocyte proliferation due to
ASC-secreted factors, ASCs also secrete pro-inflammatory
factors IL-6, 8, and 11, and TNFa [37], which may have
inhibited chondrocyte proliferation.
Although VEGF-A alone did not prevent chondrocyte
proliferation, it mitigated the ability of FGF-2 to stimulate
chondrocyte proliferation at a high concentration. Addi-
tionally, FGF-2 restored proteoglycan production in chon-
drocytes treated with VEGF-A, and high concentrations of
FGF-2 eliminated the apoptotic effect VEGF-A had on
chondrocytes. While both FGF-2 and VEGF-A are impor-
tant facilitators for angiogenesis [38,39] and their corre-
sponding mRNA levels in ASCs experienced similar
decreases when treated with chondrogenic medium, ASCs
secreted at least 10-fold less FGF-2 than VEGF-A. Further-
more, unlike VEGF-A, FGF-2 has previously been shown
to enhance the chondrogenic potential of different stem
cell sources [40,41], as well as improve cartilage regenera-
tion [42,43]. The combination of high VEGF-A secretion
and low FGF-2 secretion may be the main reason why
ASC-secreted factors have deleterious effects on chondro-
cytes and subsequent cartilage regeneration.
VEGF enhances catabolic pathways in chondrocytes, and
VEGF signaling has been associated with osteophyte for-
mation and progression of osteoarthritis in articular carti-
lage [44-46]. Moreover, blocking VEGF signaling improves
the chondrogenic potential and regenerative capacity of
muscle-derived stem cells [47,48]. Additionally, VEGF-A
Figure 6 Effects of adipose stem cells (ASCs) on cartilage regeneration. (A) Radiographic scoring with arrows highlighting the defect (n = 4
blinded scoring averages ± SE). *P < 0.05 vs. empty defect; #P < 0.05 vs. ASCs; ^P < 0.05 vs. ASC + chondrogenic medium, CM). (B) Three-
dimensional EPIC-micro computer tomography (μCT) images of xiphoids with *marking the defect and calculated cartilage volume within defects
(n = 7 ± SE). *P < 0.05 vs. empty defect; #P < 0.05 vs. ASCs. (C) Representative H&E staining. Bar represents 100 μm at 20 × magnification (D =
defect, × = xiphoid, AG = autograft).
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directs cartilage vascularization in hyaline cartilage and
hypertrophic chondrocyte absorption that leads to subse-
quent ossification [49,50]. Although chondrocytes exposed
to ASC-secreted factors did not have increased mRNA
levels corresponding to RUNX2 or increased alkaline
phosphatase activity, and cartilage defects with ASC pellets
did not have signs of vascularization, hypertrophic differ-
entiation, or bone formation, in vitro conditioned media
studies longer than 24 hours or in vivo studies longer than
35 days may have revealed these effects. Additionally,
ASCs may secrete trophic factors that prevent hyper-
trophic differentiation.
In addition to affecting hypertrophic differentiation, the
length of exposure to ASC-secreted factors and the time
points measured appear to be important variables in reg-
ulating chondrocyte phenotype. Twelve hour exposure to
ASC-conditioned medium appeared to have the most sig-
nificant effects on mRNA levels corresponding to SOX9
and aggrecan, which are earlier stage markers of chon-
drogenesis, whereas 7 days of ASC co-culture exerted the
greatest effects on mRNA levels corresponding to
RUNX2, a later stage chondrogenic marker [51]. Because
these unique phenotypic expression profiles for the dif-
ferent stages of chondrogenesis, the time points mea-
sured for the co-cultures, conditioned medium, and
subsequent studies may have affected the findings on
chondrocyte phenotypic expression, proliferation, proteo-
glycan synthesis, and apoptosis. However, these time
points are consistent with previous studies investigating
the effects different signaling molecules have on chon-
drocytes [18,19,21]. Additionally, 7-day co-culture with
ASCs treated with chondrogenic medium increased
aggrecan expression in chondrocytes, and this increase
was not observed in the conditioned media study.
Although the different time points between the two
studies may explain this discrepancy, the interplay
between chondrocyte and ASC signaling may also have a
contribution.
Several studies have investigated the effects chondro-
cyte and stem cell co-cultures and chondrocyte-secreted
factors have on stem cell differentiation [47,52,53], but
few have provided insight into the effects stem cell-
mediated paracrine signaling has on chondrocytes. Bian
et al. showed that co-culturing chondrocytes with MSCs
within the same gel reduced hypertrophy and increased
compressive moduli, but it appeared that these improve-
ments were independent of long-range MSC-paracrine
signaling [54]. Additionally, results from Hildner et al.
suggested that co-culturing ASCs and chondrocytes in
the same matrix moderately increased SOX9, aggrecan,
and cartilage oligomeric protein mRNA expression when
normalized to the initial percentage of chondrocytes, but
the findings provided little insight into the role of ASC-
secreted factors [55]. Although chondrogenic treatment
that included both TGF-b1 and BMP-6 eliminated the
deleterious effects that ASC-secreted factors and ASCs
had on chondrocytes and cartilage regeneration respec-
tively, ASCs treated with chondrogenic medium did not
secrete factors that improved the ability of chondrocytes
to produce cartilaginous extracellular matrix in vitro.
This absence of improvement over baseline may be due
to the short 5-day chondrogenic medium-treatment time
as several studies have shown optimal ASC and stem cell
chondrogenesis to require at least 2 to 6 weeks of chon-
drogenic treatment [56,57]. However, these studies did
not investigate the effects that varying the temporal
application of chondrogenic medium had on trophic fac-
tor production. Additionally, assessing cartilage regenera-
tion at longer time points post-operatively may provide
better insight into the therapeutic benefit of this group.
Conclusions
This study showed that ASCs can inhibit cartilage regen-
eration within a focal hyaline cartilage defect in vivo after
35 days. In vitro, ASC monolayers or microbeads cul-
tured in growth medium secreted a large amount of
VEGF-A, which caused chondrocyte apoptosis and
reduced proteoglycan synthesis after 24 hours of condi-
tioned media treatments. Additionally, these ASCs
secreted factors that reduced chondrogenic gene expres-
sion and proliferation after 12 and 24 hours of condi-
tioned media treatments respectively. Treating ASCs
with chondrogenic medium for 5 days reduced the secre-
tion of VEGF-A, significantly reduced the deleterious
effects ASC-secreted factors have on chondrocytes, and
eliminated the inhibitory effect ASCs have on cartilage
regeneration. Blocking VEGF-A in ASC-conditioned
medium eliminated the deleterious effects ASC-secreted
factors had on chondrocyte phenotype and apoptosis
after 24 hours. Adding a high concentration of FGF-2
eliminated the apoptotic effect VEGF-A had on chondro-
cytes, and adding both low and high concentrations of
FGF-2 eliminated the detrimental effects VEGF-A had on
chondrocyte phenotype after 24 hours. These results
have significant implications on how ASCs and possibly
other stem cell therapies are used for repairing cartilage.
Specifically, these therapies must be pre-treated or modi-
fied to reduce the inhibitory effects of VEGF-A and other
secreted factors on cartilage regeneration.
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